Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America

The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Daniel J, Tse, Karin, Hanrahan, Leslie, Davies, Rupert, Petri, Michelle A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519405/
https://www.ncbi.nlm.nih.gov/pubmed/31168400
http://dx.doi.org/10.1136/lupus-2019-000317
_version_ 1783418635883118592
author Wallace, Daniel J
Tse, Karin
Hanrahan, Leslie
Davies, Rupert
Petri, Michelle A
author_facet Wallace, Daniel J
Tse, Karin
Hanrahan, Leslie
Davies, Rupert
Petri, Michelle A
author_sort Wallace, Daniel J
collection PubMed
description The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.
format Online
Article
Text
id pubmed-6519405
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65194052019-06-05 Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America Wallace, Daniel J Tse, Karin Hanrahan, Leslie Davies, Rupert Petri, Michelle A Lupus Sci Med Brief Communication The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence. BMJ Publishing Group 2019-03-19 /pmc/articles/PMC6519405/ /pubmed/31168400 http://dx.doi.org/10.1136/lupus-2019-000317 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Brief Communication
Wallace, Daniel J
Tse, Karin
Hanrahan, Leslie
Davies, Rupert
Petri, Michelle A
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title_full Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title_fullStr Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title_full_unstemmed Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title_short Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
title_sort hydroxychloroquine usage in us patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with sle conducted by the lupus foundation of america
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519405/
https://www.ncbi.nlm.nih.gov/pubmed/31168400
http://dx.doi.org/10.1136/lupus-2019-000317
work_keys_str_mv AT wallacedanielj hydroxychloroquineusageinuspatientstheirexperiencesoftolerabilityandadherenceandimplicationsfortreatmentsurveyresultsfrom3127patientswithsleconductedbythelupusfoundationofamerica
AT tsekarin hydroxychloroquineusageinuspatientstheirexperiencesoftolerabilityandadherenceandimplicationsfortreatmentsurveyresultsfrom3127patientswithsleconductedbythelupusfoundationofamerica
AT hanrahanleslie hydroxychloroquineusageinuspatientstheirexperiencesoftolerabilityandadherenceandimplicationsfortreatmentsurveyresultsfrom3127patientswithsleconductedbythelupusfoundationofamerica
AT daviesrupert hydroxychloroquineusageinuspatientstheirexperiencesoftolerabilityandadherenceandimplicationsfortreatmentsurveyresultsfrom3127patientswithsleconductedbythelupusfoundationofamerica
AT petrimichellea hydroxychloroquineusageinuspatientstheirexperiencesoftolerabilityandadherenceandimplicationsfortreatmentsurveyresultsfrom3127patientswithsleconductedbythelupusfoundationofamerica

Ejemplares similares